NOVERA RETATRUTIDE: THE NEW HOPE FOR BODY LOSS?

Recent clinical evidence suggests that Novera Retatrutide, a combined-action therapy from Novo Nordisk, could provide a substantial step in body control. Beyond many existing treatments, Retatrutide impacts both glucagon-like peptide-1 (GLP-1) and GIP, potentially resulting to enhanced reductions